Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen

At its regular monthly meeting last week, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a number of positive opinions on new medicinal products, including the following:

• Spanish drug major Almirall’s (ALM: MC) aclidinium bromide (trade names Bretaris Genuair and Eklira Genuair, as maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease;

• Japan’s Eisai’s (TYO: 4523) Fycompa (perampanel) as adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older;